Conflicts of interest, institutional corruption, and pharma: an agenda for reform.

@article{Rodwin2012ConflictsOI,
  title={Conflicts of interest, institutional corruption, and pharma: an agenda for reform.},
  author={Marc A. Rodwin},
  journal={The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics},
  year={2012},
  volume={40 3},
  pages={
          511-22
        }
}
When physicians' conflicts of interest arise from ties with drug firms, we should shift our focus to the pharmaceutical industry and improper dependencies that cause institutional corruption. This article analyzes eight forms of improper dependencies on pharma and proposes reforms. 

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Health Care Costs and the Arc of Innovation

Neel U. Sukhatme, Maxwell Gregg Bloche
  • 2019

Trust and transparency: patient perceptions of physicians' financial relationships with pharmaceutical companies.

  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2014

Rooting out institutional corruption to manage inappropriate off-label drug use.

  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2013

Introduction: insights from a National Conference: "conflicts of interest in the practice of medicine".

  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2012

References

Publications referenced by this paper.
SHOWING 1-10 OF 55 REFERENCES

National Academies Press, 2010), available at <http://www

Institute of Medicine, Committee on Planning a Continuing Health Professional Educa Institute, D. C. Redesigning Continuing Education in the Health Washington
  • nap.edu/catalog/12704.html>
  • 2012

Putting Patient Safety First?: Hearing Before the Comm

FDA, Merck, Vioxx
  • on Fin., 186th Cong. (2004), available at <http://www.finance.senate.gov/hearings/ hearing/?id=48b33994-9de9-df09-dfb8-bb3599a92fbb>
  • 2012

Rodwin, “The Need for Independent Drug Testing for the FDA to Evaluate Whether to Grant Marketing Approval,

M A.
  • Saint Louis University Law Review
  • 2012

The Drug Industry’s Performance in Finishing Post-marketing Research (Phase IV) Studies: A Public Citizen’s Health Research Group Report, available at <http://www.citizen.org/hrg1520>

L. D. Sasich, P. Lurie, S. M. Wolfe
  • (last visited August
  • 2012

Fewer Than One in Eight Completed Studies of Drugs and Biologics Are Reported on Time on ClinicalTrials.gov,

S. Mathieu, I. Boutron, D. Moher, D. G. Altman, P. Ravaud
  • Health Affairs 30, no
  • 2011